The experimental Immunology Core Facility will provide expertise in state- of-the-art immunological procedures for used by basic and clinical CFAR investigators. Essential assays for immunology research will be provided on a fee-for-service basis. The fee structures will include a partial subsidy from the core grant, which will enable highly qualified technical personnel to be available to participate in numerous research projects. Additional objectives include training of personnel from other laboratories, and serving as a resource to provide immunological reagents to the CFAR community. The long term objectives are to facilitate research and promote collaboration among CFAR investigators. Individual components of this Core Facility include: (a) Molecular Immunology. The laboratory has developed unique expertise and reagents for analysis of cytokines, chemokines, chemokine receptors, and growth factors in non-human primates as well as human cells and tissues. (B) Flow cytometry. New flow cytometry methods have recently been introduced for detection of specific cell- mediated immune responses to HIV, including labeling of antigen-specific cells with soluble MHC-tetramers and detections of intracellular cytokines produced by specifically stimulated cells. The goal of the Emory Center for AIDS Research Flow Cytometry Facility will be to provide these new techniques, as well as traditional immunophenotyping analysis, to clinical and basic studies investigating HIV-specific immune responses in infected humans, and to apply them in primate models used for pathogenesis studies and vaccine development. (C) Evaluation of Humoral Immune Responses. This laboratory will provide standardized assays for analysis include antibody- capture ELISAs for the detection of HIV/SIV anti-gag and anti-env antibodies, CEM x 174 co-culture to detect serum neutralizing antibody responses against various HIV and SIV strains, and Western blots to examine the breadth of serologic response against HIV or SIV. (D) Confocal Microscopy and Immunohistochemistry. The confocal microscopy and immunohistochemistry facility will enable CFAR members to obtain high resolution, digital confocal images of cells. Examples of applications include localization and co-localization of viral antigens in infected cells, identification of subcellular compartments, containing viral proteins, assays of effects of localization of cellular proteins after different stimuli (e.g. capping of cell surface proteins when cells are activated), and localization of viral nucleic acids.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA012121-02
Application #
6201661
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Thomas, Ajit G; Bodner, Amos; Ghadge, Ghanashyam et al. (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15:449-57
Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-18
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67

Showing the most recent 10 out of 42 publications